Cargando…

Molecular Changes in Dengue Envelope Protein Domain III upon Interaction with Glycosaminoglycans

Dengue fever is a rapidly emerging vector-borne viral disease with a growing global burden of approximately 390 million new infections per annum. The Dengue virus (DENV) is a flavivirus spread by female mosquitos of the aedes genus, but the mechanism of viral endocytosis is poorly understood at a mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hyatt, James G., Prévost, Sylvain, Devos, Juliette M., Mycroft-West, Courtney J., Skidmore, Mark A., Winter, Anja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697694/ https://www.ncbi.nlm.nih.gov/pubmed/33187224 http://dx.doi.org/10.3390/pathogens9110935

Ejemplares similares

Diagnostic Performance of Dengue Virus Envelope Domain III in Acute Dengue Infection
por: Nguyen, Ngoc Minh, et al.
Publicado: (2019)

Glycosaminoglycans from Litopenaeus vannamei Inhibit the Alzheimer’s Disease β Secretase, BACE1
por: Mycroft-West, Courtney J., et al.
Publicado: (2021)

Dengue virus type-3 envelope protein domain III; expression and immunogenicity
por: Fahimi, Hossein, et al.
Publicado: (2014)

Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III
por: Matsui, Kiyohiko, et al.
Publicado: (2010)

Evidence of a putative glycosaminoglycan binding site on the glycosylated SARS-CoV-2 spike protein N-terminal domain
por: Schuurs, Zachariah P., et al.
Publicado: (2021)

A Glycosaminoglycan Extract from Portunus pelagicus Inhibits BACE1, the β Secretase Implicated in Alzheimer’s Disease
por: Mycroft-West, Courtney J., et al.
Publicado: (2019)

Production of dengue 2 envelope domain III in plant using CPMV - based vector system
por: Carlos Marques, Lívia Érika, et al.
Publicado: (2014)

Immunogenicity of a novel tetravalent dengue envelope protein domain III-based antigen in mice
por: Fahimi, Hossein, et al.
Publicado: (2018)

Addition of Partial Envelope Domain II into Envelope Domain III of Dengue Virus Antigen Potentiates the Induction of Virus-Neutralizing Antibodies and Induces Protective Immunity
por: Park, Jisang, et al.
Publicado: (2020)

Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus
por: Harahap-Carrillo, Indira S., et al.
Publicado: (2015)

In silico binding analysis of lutein and rosmarinic acid against envelope domain III protein of dengue virus
por: Panchal, Ritesh, et al.
Publicado: (2021)

DNA Vaccines against Dengue Virus Type 2 Based on Truncate Envelope Protein or Its Domain III
por: Azevedo, Adriana S., et al.
Publicado: (2011)

Casamino acids facilitate the secretion of recombinant dengue virus serotype-3 envelope domain III in Pichia pastoris
por: Kaushik, Neha, et al.
Publicado: (2016)

In silico analysis of an envelope domain III-based multivalent fusion protein as a potential dengue vaccine candidate
por: Fahimi, Hossein, et al.
Publicado: (2016)

Characterization of a Novel Dengue Serotype 4 Virus-Specific Neutralizing Epitope on the Envelope Protein Domain III
por: Ji, Guang-Hui, et al.
Publicado: (2015)

A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III
por: Hu, Dan, et al.
Publicado: (2019)

Expression of an immunocomplex consisting of Fc fragment fused with a consensus dengue envelope domain III in Saccharomyces cerevisiae
por: So, Kum-Kang, et al.
Publicado: (2021)

Dengue-1 Envelope Protein Domain III along with PELC and CpG Oligodeoxynucleotides Synergistically Enhances Immune Responses
por: Chiang, Chen-Yi, et al.
Publicado: (2012)

Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice
por: Chiang, Chen-Yi, et al.
Publicado: (2016)

Neutralizing Antibody Response and Efficacy of Novel Recombinant Tetravalent Dengue DNA Vaccine Comprising Envelope Domain III in Mice
por: Kulkarni, Ajit, et al.
Publicado: (2017)

Dengue Virus Envelope Protein Domain III Induces Nlrp3 Inflammasome-Dependent NETosis-Mediated Inflammation in Mice
por: Lien, Te-Sheng, et al.
Publicado: (2021)

Exposure to Dengue Envelope Protein Domain III Induces Nlrp3 Inflammasome-Dependent Endothelial Dysfunction and Hemorrhage in Mice
por: Lien, Te-Sheng, et al.
Publicado: (2021)

Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2
por: Arora, Upasana, et al.
Publicado: (2012)

Simulation of Hemorrhage Pathogenesis in Mice through Dual Stimulation with Dengue Envelope Protein Domain III-Coated Nanoparticles and Antiplatelet Antibody
por: Lien, Te-Sheng, et al.
Publicado: (2023)

Release of Sequestered Malaria Parasites upon Injection of a Glycosaminoglycan
por: Vogt, Anna M, et al.
Publicado: (2006)

Structural Insight into Non-Enveloped Virus Binding to Glycosaminoglycan Receptors: A Review
por: Sorin, Marie N., et al.
Publicado: (2021)

Phage Display Approaches for the Isolation of Monoclonal Antibodies Against Dengue Virus Envelope Domain III from Human and Mouse Derived Libraries
por: Moreland, Nicole J., et al.
Publicado: (2012)

The Immunodominance Change and Protection of CD4(+) T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice
por: Chen, Hsin-Wei, et al.
Publicado: (2015)

Actin Interacts with Dengue Virus 2 and 4 Envelope Proteins
por: Jitoboam, Kunlakanya, et al.
Publicado: (2016)

Sulfated Escherichia coli K5 Polysaccharide Derivatives Inhibit Dengue Virus Infection of Human Microvascular Endothelial Cells by Interacting with the Viral Envelope Protein E Domain III
por: Vervaeke, Peter, et al.
Publicado: (2013)

Evaluation of envelope domain III-based single chimeric tetravalent antigen and monovalent antigen mixtures for the detection of anti-dengue antibodies in human sera
por: Batra, Gaurav, et al.
Publicado: (2011)

A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies
por: Chua, Anthony JS, et al.
Publicado: (2013)

Cross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the envelope proteins
por: Zidane, Nora, et al.
Publicado: (2013)

Lipidated Dengue-2 Envelope Protein Domain III Independently Stimulates Long-Lasting Neutralizing Antibodies and Reduces the Risk of Antibody-Dependent Enhancement
por: Chiang, Chen-Yi, et al.
Publicado: (2013)

Production of tetravalent dengue virus envelope protein domain III based antigens in lettuce chloroplasts and immunologic analysis for future oral vaccine development
por: van Eerde, André, et al.
Publicado: (2019)

Epitope Presentation of Dengue Viral Envelope Glycoprotein Domain III on Hepatitis B Core Protein Virus-Like Particles Produced in Nicotiana benthamiana
por: Pang, Ee Leen, et al.
Publicado: (2019)

Exposure of Platelets to Dengue Virus and Envelope Protein Domain III Induces Nlrp3 Inflammasome-Dependent Platelet Cell Death and Thrombocytopenia in Mice
por: Lien, Te-Sheng, et al.
Publicado: (2021)

Glycosaminoglycan Domain Mapping of Cellular Chondroitin/Dermatan Sulfates
por: Persson, Andrea, et al.
Publicado: (2020)

Pleiotrophin Interaction with Synthetic Glycosaminoglycan Mimetics
por: Miles, Jonathan R., et al.
Publicado: (2022)

Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies
por: Tripathi, Lav, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vlas3r7uets56vaq7og9r7l2ev